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ABSTRACT
PURPOSE: To evaluate effects of ischemic preconditioning and Cilostazol on muscle ischemia-reperfusion injury. 
METHODS: Male Wistar rats were submitted to muscle ischemic and reperfusion injury (4h of the left common iliac artery occlusion 
followed by 1h of reperfusion). Five experimental groups were constituted: Control group (n=4); Ischemia-Reperfusion (IR, n=5); 
Ischemic preconditioning group (IP, n=6); Ischemia-Reperfusion group treated with cilostazol (IRCi, n=6) and Ischemic preconditioning 
group treated with cilostazol (IPCi, n=6). At the end, left gracile muscle was removed and embedded in paraffin. Histopathology, 
neutrophil infiltration, myocyte necrosis and edema were analyzed.
RESULTS: When compared with the control group, IR group showed increased neutrophil infiltration, severe necrosis and edema. There 
was significant difference between myocytes necrosis of IR group and IP group. There was no difference between the histopathological 
changes between IP, IRCi and IPCi groups. 
CONCLUSIONS: The model of IR caused severe muscle injury in the rat hind limb and ischemic preconditioning has a protective 
effect, reducing myocyte necrosis, however, treatment with cilostazol and also the association between cilostazol and preconditioning 
has no protective effect on the skeletal muscle subjected to ischemia and reperfusion injury.
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Introduction
Despite the development of reconstructive surgery techniques 
have led the possibility to preservation of members function affected 
by severe trauma or resection of malignant musculoskeletal tumors, 
ischemia and reperfusion (IR) injury remain as the major cause of 
failure of transfer of tissues, leading to extensive surgical revisions 
or amputation of the extremity1,2. IR injury happens when ,during 
ischemia, blood flow interruption creates local lesions in proportion 
to oxygen and nutriment privation time, urging reperfusion to be 
performed as soon as possible. However, reperfusion itself induces 
more cellular alterations, likely through mitochondrial dysfunction, 
increased reactive oxygen species production, and inflammation3,4,5.
Several methods, such as thrombolytic agents, hyperbaric 
oxygen treatment, and anti-inflammatory agents have been tested 
to prevent or lessen the harmful effects of IR injury 6. It has been 
shown that Ischemic Preconditioning (IP) confers natural tissue 
protection to prolonged ischemic stress, involving multiple 
mediators of ischemic damage such as adenosine, norepinephrine, 
bradykinin, and unidentified opioids 7. IP in skeletal muscle 
has showed a protective effect in vascular reperfusion, cellular 
membrane structure and function, muscle preservation, decreasing 
inflammatory infiltrate and vascular stasis 8-12.
On the other hand, cilostazol is a potent and selective 
inhibitor of phosphodiesterase III. This enzyme increases cyclic 
adenosine 3 ‘, 5’-monophosphate (c AMP) in thrombocytes 
and smooth muscle cells decreasing intracellular calcium with 
consequent relaxation and vasodilation. AMPc, in turn, is a 
regulator of immune and inflammatory responses13. 
The protective action of cilostazol in IR injury has been 
demonstrated in the central nervous system, 14, 15 renal tissue 
6, heart 17 and in chronic arterial disease16. But the protective 
role of this drug in acute IR injury of skeletal muscle is not yet 
established. Studies have indicated the protective role of this drug 
in skeletal muscle, through the effect on endothelium dependent 
vascular reactivity 19, however, no decrease in muscle damage as a 
biomarker of serum myoglobin muscle and other histopathological 
changes and apoptosis using cilostazol was observed in IR muscle 
models20.21. The effects of IP associated with cilostazol treatment in 
muscle ischemia-reperfusion injury did not studied yet. The aim of 
this study was evaluate the effects of IP associated with cilostazol 
in experimental model of muscle ischemia-reperfusion injury. 
Methods 
All animals were handled according to the ethical 
principles of laboratory animal care according to law 11.794, 
October 8, 2008, which governs the ethical use of animals for 
experimentation and followed the guidelines by the Research 
Ethics Committee of the UNIFESP.
Adult male Wistar rats (Rattus norvegicus albinus), 
aged between 90 and 120 d and weighing between 250 and 300 
g, were used. The animals were kept six days for observation 
and adaptation, in appropriate cages (40 X 30 X 25 cm), with a 
maximum of five animals per cage, under controlled conditions 
for light, temperature, and daily hygiene. They received water and 
balanced chow ad libitum.
Experimental groups 
The animals were randomly distributed into the following 
groups: Control group (CG, n=4): These animals were submitted 
to the anesthesia and the surgical procedure, without IR injury 
induction; Ischemia-Reperfusion group (IR, n=5): These animals 
were submitted to a prolonged ischemia (4hs) and reperfusion (1h); 
Ischemic preconditioning group (IP, n=6): These animals were 
submitted to a PCI (10x10 minutes) before prolonged ischemia 
(4hs) and reperfusion (1h); Ischemia-Reperfusion group treated 
with cilostazol (IRCi, n=6): These animals received 30mg/kg of 
cilostazol before prolonged ischemia (4hs) and reperfusion (1h); 
Ischemic preconditioning group treated with cilostazol (IPCi, 
n=6): These animals received 30mg/kg of cilostazol and PCI (10 x 
10 minutes) before prolonged ischemia (4hs) and reperfusion (1h).
Induction of IR injury of skeletal muscle
The animals were anesthetized with a combination of 
ketamine (50 mg/kg) and xylazine (15 mg/kg) via intramuscularly 
injection. The animals were considered anesthetized when 
they were unresponsive to mechanical stimuli, being unable to 
withdraw the hind limb after pain stimulus and also presented 
absence of palpebral reflexes. Additional doses of anesthesia (half 
of the initial dose) were administered approximately every 50 min. 
The animals were also kept well ventilated at room temperature. 
The animals were placed on a constantly heated plate (37°C) in 
supine position with hind limbs immobilized and adhesive tape 
across the chest. Trichotomy was performed on the abdomen 
region with a razor blade followed by antisepsis of the operative 
area with iodine polyvinylpyrrolidone tincture.
Using a no. 11 scalpel blade, a skin incision was made, 
with dissection and isolation of the left common iliac artery. This 
artery was clamped during 4 hours and then, the clamp was removed. 
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The animals were observed for more 1 hour, at which 
time they were euthanized by lethal dose of anesthetic.
Cilostazol and Ischemic preconditioning 
Cilostazol were dissolved in dimethyl sulphoxide 
and injected intraperitoneally (30mg/kg) 20 minutes before of 
prolonged ischemia.
The Ischemic preconditioning consisted of 10 minutes 
occlusion of the left common iliac artery occlusion followed by 10 
minutes of reperfusion, before prolonged ischemia.  
Collecting gracile muscle and histopathology
After euthanasia, left inferior gracile muscle was excised, 
fixed in formalin solution, embedded in paraffin. Five micrometer 
sections were stained with hematoxylin-eosin (HE) and Neutrophil 
infiltration, muscular edema and signs of myocyte necrosis were 
evaluated under 100x of magnification and blinded manner by 
score method: absent (0), rare (1), moderate (2) and severe (3).
There were considered signs of myocyte necrosis: cellular 
vacuolization, band contraction and/or cellular destruction.  
Statistical analysis
The data were analyzed using the SigmaStat statistical 
program, version 3.1 (Systat Software, SanJose, CA). The groups 
were compared by Kruskal-Wallis 1-way analysis of variance 
on ranks, after testing for normality and variance equality, and 
complemented by post hoc test (Dunn’s test). The groups were also 
compared in pairs using the Mann Whitney test. Data were expressed 
median (25%-75%). Difference was considered statistically 
significant when P < 0.05.
Results
In table 1 are depict histological evaluation and in Figure 













































TABLE 1. Qualitative histological evaluation of muscle edema, myocite necrosis and neutrophil infiltration of gracile muscle of rats 
submitted to ischemia-reperfusion injury.
IR: Ischemia-reperfusion injury; Ci: cilostazol; IP: ischemic preconditioning. Values are presented on 
mean±standart error followed to median (25%-75%).
FIGURE 1 – Photomicrographs depicting gracile muscle from rats submitted o ischemia-reperfusion injury (IR) with or without cilostazol (Ci) 
treatment and/or ischemic preconditioning (IP) compared to control rats. Right top panels show intense inflammatory cell infiltration, edema and 
myocyte necrosis from IR group in contrast with normal tissue from Control group. Bottom panels show reduction of inflammation, necrosis and/or 
edema in groups submitted to IP or treated by cilostazol. HE, 100X
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In the table 2, p-values obtained by comparing the 
experimental groups and the IR group is depicted. Prolonged 
ischemia of the left hind limb and reperfusion promotes intense 
neutrophil infiltration, necrosis and edema within gracile muscle. 
The IP group appeared to reduce myocyte necrosis in muscle 
tissue, but cilostazol or the association between preconditioning 
and cilostazol did not protect skeletal muscle from IR injury.
accordance with these studies, we also observed the protective 
effect of IP in this experimental model of IR Injury, especially 
with the reduction of myocyte necrosis.
Previously studies suggest that cilostazol could have 
a protective effect by perfusion increasing in ischemic areas 
and anti-apoptotic properties 23,24. In addition, other studies have 
observed that cilostazol has a protective effect against ischemic 
injury in animal models, when observed in other organs25,26. 
Francischetti et al.27 demonstrated that cilostazol 
reduces oxidative stress in rats subjected to 45 min of spinal 
cord ischemia by aortic clamping and reperfusion period of 48 
hours. The biochemical and histopathological examination of 
animals treated with a dose of cilostazol 20 mg / kg orally for 
three days before spinal cord ischemia, demonstrated a reduction 
in neurological damage.
However, in this study, histopathological changes due 
to ischemia and reperfusion in animals treated with cilostazol in 
striated muscle were observed at a lower intensity, but without 
statistical difference when compared with the IR group animals. 
These results are consistent with the study of Moreira Neto et 
al.28 who found no protective effects of cilostazol in IR injury of 
skeletal muscle in similar experimental models with a reperfusion 
periods of 2 hours and 6 hours.
Cilostazol treatment alone or in combination with IP 
showed no significant effect on muscle injury protection in IR and 
suggests that more experimental studies are required to elucidate 
the role of these strategies in the treatment of muscle injury IR.
Conclusion
 The model of IR caused severe muscle injury in the rat 
hind limb and ischemic preconditioning has a protective effect, 
reducing myocyte necrosis, however, despite signs that treatment 
with cilostazol and also the association between cilostazol and 
preconditioning could have a protective effect on this injury, this 
was not observed in this study.
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